On the other hand, in a randomized phase 3 trial of 1205 patients with locally advanced PC staged at cT3-4N0/NXM0, cT1–2 + PSA > 40 ng/mL, or cT1–2 + PSA 20–40 ng/mL + GS 8–10, the 10-year OS of patients treated with combined ADT and RT was significantly better than that of patients treated with ADT alone, at 55% and 49%, respectively (HR: 0.70; 95% CI: 0.57–0.85; p < 0.001), and the risk of death was reduced by 30% [5]. The gene discussed is KLK3; the disease is pachyonychia congenita.